Triad Wealth Partners LLC Purchases Shares of 1,007 Veeva Systems Inc. (NYSE:VEEV)

Triad Wealth Partners LLC purchased a new stake in Veeva Systems Inc. (NYSE:VEEV) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,007 shares of the technology company’s stock, valued at approximately $212,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Keybank National Association OH increased its holdings in Veeva Systems by 22.0% in the 4th quarter. Keybank National Association OH now owns 3,042 shares of the technology company’s stock valued at $640,000 after buying an additional 549 shares during the period. Torray Investment Partners LLC increased its holdings in Veeva Systems by 0.7% in the 4th quarter. Torray Investment Partners LLC now owns 32,813 shares of the technology company’s stock valued at $6,899,000 after buying an additional 242 shares during the period. State of Michigan Retirement System increased its holdings in Veeva Systems by 1,600.0% in the 4th quarter. State of Michigan Retirement System now owns 30,600 shares of the technology company’s stock valued at $6,434,000 after buying an additional 28,800 shares during the period. Fidelis Capital Partners LLC bought a new stake in Veeva Systems in the 4th quarter valued at $222,000. Finally, LGT Fund Management Co Ltd. increased its holdings in Veeva Systems by 95.3% in the 4th quarter. LGT Fund Management Co Ltd. now owns 33,249 shares of the technology company’s stock valued at $6,991,000 after buying an additional 16,225 shares during the period. Institutional investors own 88.20% of the company’s stock.

Veeva Systems Trading Up 0.9 %

Veeva Systems stock opened at $220.32 on Thursday. Veeva Systems Inc. has a 1 year low of $170.25 and a 1 year high of $258.93. The company has a market cap of $35.77 billion, a PE ratio of 54.40, a PEG ratio of 1.89 and a beta of 0.85. The company’s 50-day moving average is $223.82 and its two-hundred day moving average is $219.54.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $270.00 price target on shares of Veeva Systems in a report on Friday, January 17th. Mizuho started coverage on shares of Veeva Systems in a report on Wednesday, December 4th. They issued an “outperform” rating and a $275.00 target price on the stock. The Goldman Sachs Group lowered shares of Veeva Systems from a “buy” rating to a “sell” rating and lowered their target price for the stock from $261.00 to $200.00 in a report on Thursday, January 23rd. Robert W. Baird upped their target price on shares of Veeva Systems from $275.00 to $283.00 and gave the stock an “outperform” rating in a report on Friday, December 6th. Finally, Stifel Nicolaus upped their target price on shares of Veeva Systems from $240.00 to $272.00 and gave the stock a “buy” rating in a report on Friday, December 6th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Veeva Systems has an average rating of “Moderate Buy” and a consensus price target of $254.48.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.